MicroRNAs involved in the mitogen-activated protein kinase cascades pathway during glucose-induced cardiomyocyte hypertrophy.

Cardiac hypertrophy is a key structural feature of diabetic cardiomyopathy in the late stage of diabetes. Recent studies show that microRNAs (miRNAs) are involved in the pathogenesis of cardiac hypertrophy in diabetic mice, but more novel miRNAs remain to be investigated. In this study, diabetic cardiomyopathy, characterized by hypertrophy, was induced in mice by streptozotocin injection. Using microarray analysis of myocardial tissue, we were able to identify changes in expression in 19 miRNA, of which 16 miRNAs were further validated by real-time PCR and a total of 3212 targets mRNA were predicted. Further analysis showed that 31 GO functions and 16 KEGG pathways were enriched in the diabetic heart. Of these, MAPK signaling pathway was prominent. In vivo and in vitro studies have confirmed that three major subgroups of MAPK including ERK1/2, JNK, and p38, are specifically upregulated in cardiomyocyte hypertrophy during hyperglycemia. To further explore the potential involvement of miRNAs in the regulation of glucose-induced cardiomyocyte hypertrophy, neonatal rat cardiomyocytes were exposed to high glucose and transfected with miR-373 mimic. Overexpression of miR-373 decreased the cell size, and also reduced the level of its target gene MEF2C, and miR-373 expression was regulated by p38. Our data highlight an important role of miRNAs in diabetic cardiomyopathy, and implicate the reliability of bioinformatics analysis in shedding light on the mechanisms underlying diabetic cardiomyopathy.

[1]  Fabio Martelli,et al.  MicroRNA-210 as a Novel Therapy for Treatment of Ischemic Heart Disease , 2010, Circulation.

[2]  M. Hsiao,et al.  MicroRNA-373 (miR-373) post-transcriptionally regulates large tumor suppressor, homolog 2 (LATS2) and stimulates proliferation in human esophageal cancer. , 2009, Experimental cell research.

[3]  Susumu Goto,et al.  The KEGG resource for deciphering the genome , 2004, Nucleic Acids Res..

[4]  A. Grishman,et al.  New type of cardiomyopathy associated with diabetic glomerulosclerosis. , 1972, The American journal of cardiology.

[5]  K. Aonuma,et al.  Contributory role of VEGF overexpression in endothelin-1-induced cardiomyocyte hypertrophy. , 2007, American journal of physiology. Heart and circulatory physiology.

[6]  E. Olson,et al.  MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. , 2007, The Journal of clinical investigation.

[7]  Jun Ni,et al.  Clustering of gene expression data: performance and similarity analysis , 2006, First International Multi-Symposiums on Computer and Computational Sciences (IMSCCS'06).

[8]  E. Olson,et al.  A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure , 2006, Proceedings of the National Academy of Sciences.

[9]  I. Komuro,et al.  Roles of cardiac transcription factors in cardiac hypertrophy. , 2003, Circulation research.

[10]  R. Kothary,et al.  MEF2 is upregulated during cardiac hypertrophy and is required for normal post-natal growth of the myocardium , 1999, Current Biology.

[11]  Ming Yi,et al.  WholePathwayScope: a comprehensive pathway-based analysis tool for high-throughput data , 2006, BMC Bioinformatics.

[12]  P. Khatri,et al.  A systems biology approach for pathway level analysis. , 2007, Genome research.

[13]  Mariette Schrier,et al.  A Genetic Screen Implicates miRNA-372 and miRNA-373 As Oncogenes in Testicular Germ Cell Tumors , 2006, Cell.

[14]  Carol Friedman,et al.  PhenoGO: an integrated resource for the multiscale mining of clinical and biological data , 2009, BMC Bioinformatics.

[15]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[16]  Jian-Fu Chen,et al.  MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. , 2009, The Journal of clinical investigation.

[17]  Ying Li,et al.  Rac1 Is Required for Cardiomyocyte Apoptosis During Hyperglycemia , 2009, Diabetes.

[18]  G. Dorn,et al.  Cytoplasmic signaling pathways that regulate cardiac hypertrophy. , 2001, Annual review of physiology.

[19]  N. Alenina,et al.  Induction and analysis of cardiac hypertrophy in transgenic animal models. , 2005, Methods in molecular medicine.

[20]  S. Ogawa,et al.  Involvement of gp130-mediated signaling in pressure overload-induced activation of the JAK/STAT pathway in rodent heart , 2005, Heart and Vessels.

[21]  W. Koch,et al.  Cardiac Overexpression of a Gq Inhibitor Blocks Induction of Extracellular Signal–Regulated Kinase and c-Jun NH2-Terminal Kinase Activity in In Vivo Pressure Overload , 2001, Circulation.

[22]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[23]  S. Chakrabarti,et al.  Regulation of cardiomyocyte hypertrophy in diabetes at the transcriptional level. , 2008, American journal of physiology. Endocrinology and metabolism.

[24]  W. Rottbauer,et al.  MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts , 2008, Nature.

[25]  Jian Luo,et al.  Methyl-CpG binding protein MBD2 is implicated in methylation-mediated suppression of miR-373 in hilar cholangiocarcinoma. , 2011, Oncology reports.

[26]  Vijay G Divakaran,et al.  The Emerging Role of MicroRNAs in Cardiac Remodeling and Heart Failure , 2008, Circulation research.

[27]  Chaoqian Xu,et al.  The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2 , 2011, Nature Medicine.

[28]  S. Ogawa,et al.  Role of angiotensin II in activation of the JAK/STAT pathway induced by acute pressure overload in the rat heart. , 1997, Circulation research.

[29]  Jeffrey E. Thatcher,et al.  Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis , 2008, Proceedings of the National Academy of Sciences.

[30]  Qing‐Yu He,et al.  Global identification of miR‐373‐regulated genes in breast cancer by quantitative proteomics , 2011, Proteomics.

[31]  J. Molkentin,et al.  Regulation of MEF2 by p38 MAPK and its implication in cardiomyocyte biology. , 2000, Trends in cardiovascular medicine.

[32]  F. Tsai,et al.  Effects of insulin replacement on cardiac apoptotic and survival pathways in streptozotocin‐induced diabetic rats , 2009, Cell biochemistry and function.

[33]  S. Chakrabarti,et al.  miR133a regulates cardiomyocyte hypertrophy in diabetes , 2010, Diabetes/metabolism research and reviews.

[34]  C. Ruwhof,et al.  Mechanical stress-induced cardiac hypertrophy: mechanisms and signal transduction pathways. , 2000, Cardiovascular research.

[35]  R. Malik,et al.  Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. , 2004, Clinical science.

[36]  T. Peng,et al.  Deficiency of Rac1 Blocks NADPH Oxidase Activation, Inhibits Endoplasmic Reticulum Stress, and Reduces Myocardial Remodeling in a Mouse Model of Type 1 Diabetes , 2010, Diabetes.

[37]  Danish Sayed,et al.  MicroRNAs Play an Essential Role in the Development of Cardiac Hypertrophy , 2007, Circulation research.

[38]  Chunxiang Zhang,et al.  MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy? , 2007, The American journal of pathology.

[39]  R. Plasterk,et al.  Micro RNAs in Animal Development , 2006, Cell.

[40]  K. Iczkowski,et al.  MicroRNAs 373 and 520c are downregulated in prostate cancer, suppress CD44 translation and enhance invasion of prostate cancer cells in vitro. , 2009, International journal of clinical and experimental pathology.

[41]  Li Ni,et al.  A procedure for assessing GO annotation consistency , 2005, ISMB.

[42]  Anthony J. Muslin,et al.  MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. , 2008, Clinical science.

[43]  Thomas H Marwick,et al.  Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. , 2004, Endocrine reviews.

[44]  T. Parker,et al.  Peptide growth factors can provoke "fetal" contractile protein gene expression in rat cardiac myocytes. , 1990, The Journal of clinical investigation.

[45]  A. Heagerty,et al.  Diabetic cardiomyopathy--a distinct disease? , 2009, Best practice & research. Clinical endocrinology & metabolism.

[46]  S. Kudoh,et al.  Calcineurin Plays a Critical Role in the Development of Pressure Overload–Induced Cardiac Hypertrophy , 2001, Circulation.

[47]  H. Katus,et al.  Wnt Signaling Is Critical for Maladaptive Cardiac Hypertrophy and Accelerates Myocardial Remodeling , 2010, Hypertension.

[48]  S. Izumo,et al.  Inhibition of mTOR Signaling With Rapamycin Regresses Established Cardiac Hypertrophy Induced by Pressure Overload , 2004, Circulation.